Accès gratuit
Med Sci (Paris)
Volume 20, Numéro 5, Mai 2004
Page(s) 593 - 598
Section Histoire et sciences sociales
Publié en ligne 15 mai 2004
  1. Onusida. Mise à jour des données épidémiologiques sur le VIH, décembre 2002, 38 pages.
  2. Onusida. Survol de l’épidémie dans le monde. Rapport sur l’épidémie mondiale de VIH/sida 2002, chapitre 2 : 21–42.
  3. Onusida. Rapport sur l’épidémie mondiale de VIH/sida 2002. 214 pages.
  4. Buvé A, Bishikwabo-Nsarhaza K, Mutangadura G. The spread and effect of HIV-1 infection in sub-Saharan Africa. Lancet 2002; 359 : 2001–17.
  5. Zhu T, Korber B, Nahmias A, et al. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 1998; 391 : 594–7.
  6. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000; 288 : 1789–96.
  7. Quinn T. Global burden of the HIV pandemic. Lancet 1996; 348 : 99–106.
  8. Peeters M, Sharp P. Genetic diversity of HIV-1 : The moving target. AIDS 2000; 14 : 129–40.
  9. Buvé A, Caraël M, Hayes R, et al. The multicentre study on factors determining the differential spread of HIV in four African cities : Summary and conclusions. AIDS 2001; 15 : 127–31.
  10. Banque mondiale. Rapport sur le développement dans le monde 1993 : investir dans la santé. Paris, 1993, 340 p.
  11. Djomand G, Greenberg AE, Sassan-Morokro M, et al. The epidemic of HIV/AIDS in Abidjan, Côte d’Ivoire : A review of data collected by projet RETRO-CI from 1987 to 1993. J Acquir Immune Def Syndr Hum Retrovir 1995; 10 : 358–65.
  12. Anglaret X, Gnangbomon J, Coulibaly-Koné S, et al. Clinical and immunological stages of HIV-infected patients attending community clinics, Abidjan, Côte d’Ivoire. Int J STD AIDS 1998; 9 : 432–3.
  13. Grant A, Djomand G, Smets P, et al. Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV-infected adults in Abidjan, Côte d’Ivoire. AIDS 1997; 11 : 1357–64.
  14. Kamanfu G, Mlika-Cabanne N, Girard P, et al. Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi. Am Rev Respir Dis 1993; 147 : 658–63.
  15. Brindle RJ, Nunn PP, Batchelor BI, et al. Infection and morbidity in patients with tuberculosis in Nairobi, Kenya. AIDS 1993; 7 : 1469–74.
  16. Clerinx J, Bogaerts J, Taelman H, et al. Chronic diarrhoea among adults in Kigali, Rwanda : association with bacterial enteropathogens, rectocolonic inflammation, and human immunodeficiency virus infection. Clin Infect Dis 1995; 21 : 1282–4.
  17. Malin A, Gwanzura L, Klein S, et al. Pneumocystis carinii pneumonia in Zimbabwe. Lancet 1995; 346 : 1258–61.
  18. Daley C, Mugusi F, Chen L, et al. Pulmonary complications of HIV infection in Dar es Salaam, Tanzania. Role of bronchoscopy and bronchoalveolar lavage. Am J Respir Crit Care Med 1996; 154 : 105–10.
  19. Jones N, Huebner R, Khoosal M, et al. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998; 12 : 2177–84.
  20. Archibald L, McDonald L, Nwanyanwu O, et al. A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi : implications for diagnosis and therapy. J Infect Dis 2000; 181 : 1414–20.
  21. Batungwanayo J, Taelman H, Allen S, et al. Pleural effusion, tuberculosis and HIV-1 infection in Kigali, Rwanda. AIDS 1993; 7 : 73–9.
  22. Batungwanayo J, Taelman H, Lucas S, et al. Pulmonary disease associated with the human immunodeficiency virus in Kigali, Rwanda : a fibre optic bronchoscopic study of 111 cases of undetermined etiology. Am J Respir Crit Care Med 1994; 6 : 1591–6.
  23. Gilks C, Brindle R, Otieno L, et al. Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Lancet 1990; 346 : 545–9.
  24. Scott J, Hall A, Muyodi C, et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 2000; 355 : 1225–30.
  25. Vugia DJ, Kiehlbauch JA, Yeboue K, et al. Pathogens and predictors of fatal septicemia associated with the human immunodeficiency virus infection in Ivory Coast, West Africa. J Infect Dis 1993; 168 : 564–70.
  26. Mwachari C, Batchelor B, Paul J, et al. Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. J Infect 1998; 37 : 48–53.
  27. Germani Y, Minssart P, Vohito M, et al. Etiologies of acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African republic, in relation to human immunodeficiency virus serostatus. Am J Trop Med Hyg 1998; 59 : 1008–14.
  28. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993; 7 : 1569–79.
  29. Leroy V, Msellati P, Lepage P, et al. Natural history of HIV-1 infection in African women : a prospective cohort study in Kigali, Rwanda, 1988-1993. J Acquir Immune Def Syndr 1995; 9 : 415–21.
  30. Gilks C, Ojoo S, Brindle R, et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996; 347 : 718–23.
  31. French N, Nakiyingi J, Carpenter L, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults : double-blind, randomised and placebo controlled trial. Lancet 2000; 355 : 2106–11.
  32. Perriëns JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaïre. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332 : 779–84.
  33. Allen S, Batungwanayo J, Kerlikowske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am J Med 1992; 146 : 1439–44.
  34. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocytes counts in HIV-infected persons with tuberculosis in Abidjan, Côte d’Ivoire. Lancet 1995; 345 : 607–10.
  35. Morgan D, Maude G, Malambra S, et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet 1997; 350 : 245–50.
  36. Sewankambo N, Gray R, Ahmad S, et al. Mortality associated with HIV infection in rural Rakai District, Uganda. AIDS 2000; 14 : 2391–400.
  37. French N, Mujugira A, Nakiyingi J, et al. Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. J Acquir Immune Def Syndr 1999; 22 : 509–16.
  38. Malamba S, Morgan D, Clayton T, et al. The prognostic value of the World health organisation staging system for HIV infection and disease in rural Uganda. AIDS 1999; 13 : 2555–62.
  39. Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosppression on malaria parasitemia and clinical episodes in adults in rural Uganda. Lancet 2000; 356 : 1051–6.
  40. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimetoprim-sulphamethoxazole for HIV-1 infected adults in Abidjan, Côte d’Ivoire : a randomised trial. Lancet 1999; 353 : 1462–8.
  41. Anglaret X, Messou E, Ouassa T, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis, Abidjan, Côte d’Ivoire. AIDS 2003; 17 : 575–84.
  42. De Cock K, Chaisson R. Will DOTS do it ? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999; 3 : 457–65.
  43. Whalen C, Jonhson J, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337 : 801–8.
  44. Unaids/WHO. Preventive therapy against tuberculosis in people living with HIV. Wkly Epidemiol Rec 1999; 74 : 385–400.
  45. Quigley M, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15 : 215–22.
  46. Fitzgerald D, Desvarieux M, Severe P, et al. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals : a randomised trial. Lancet 2000; 356 : 1470–4.
  47. Wiktor S, Sassan-Morokro M, Grant A, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d’Ivoire : a randomised controlled trial. Lancet 1999; 353 : 1469–75.
  48. Unaids/WHO. Provisional WHO/Unaids secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. 2000 :
  49. Anglaret X, Dabis F, Batungwanayo J, et al. Chimioprophylaxie primaire de la tuberculose chez les séropositifs dans les pays non industrialisés. Santé 1997; 7 : 89–94.
  50. Boeree M, Harries A, Zijlstra E, et al. Co-trimoxazole in HIV-1 infection. Lancet 1999; 354 : 334.
  51. Iyer J, Milhous W, Cortese J, et al. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 2001; 358 : 1066–7.
  52. Martin J, Rose D, Hadley W, et al. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. J Infect Dis 1999; 180 : 1809–18.
  53. Anglaret X. Cotrimoxazole prophylaxis in sub-Saharan Africa. Lancet 2001; 358 : 1027–8.
  54. Weidle P, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda : patients’ response, survival, and drug resistance. Lancet 2002; 360 : 34–40.
  55. Laurent C, Diakhate N, Gueye N, et al. The Senegalese government’s highly active antiretroviral therapy initiative : an 18-month follow-up study. AIDS 2002; 16 : 1363–70.
  56. Seyler C, Anglaret X, Dakoury-Dogbo N, et al. Medium-term survival, morbidity, and immuno-virological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d’Ivoire. Antivir Ther 2003; 8 : 385–93.
  57. Race E, Adelson-Mitty J, Kriegel G, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351 : 252–5.
  58. French M, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1 : 107–15.
  59. Heath K, Singer J, O’Shaughnessy M, et al. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Def Syndr 2002; 31 : 211–7.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.